Literature DB >> 25270915

Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire.

Jeanette Wilburn1, Stephen P McKenna, James Twiss, Matthew Rouse, Mariusz Korkosz, Roman Jancovic, Petr Nemec, César Francisco Pacheco-Tena, Alain Saraux, Rene Westhovens, Patrick Durez, Mona Martin, Marika Tammaru.   

Abstract

The Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire was developed directly from rheumatoid arthritis (RA) patients in the United Kingdom and the Netherlands to measure quality of life (QoL). Since then, it has become widely used in clinical studies and trials and has been adapted for use in 24 languages. The objective was to develop and validate 11 additional language versions of the RAQoL in US English, Mexican Spanish, Argentinean Spanish, Belgian French, Belgian Flemish, French, Romanian, Czech, Slovakian, Polish and Russian. The language adaptation and validation required three stages: translation, cognitive debriefing interviews and validation survey. The translation process involved a dual-panel methodology (bilingual panel followed by a lay panel). The validation survey tested the psychometric properties of the new scales and included either the Nottingham Health Profile (NHP) or the Health Assessment Questionnaire (HAQ) as comparators. Internal consistency of the new language versions ranged from 0.90 to 0.97 and test-retest reliability from 0.85 to 0.99. RAQoL scores correlated as expected with the HAQ. Correlations with NHP sections were as expected: highest with energy level, pain and physical mobility and lowest with emotional reactions, sleep disturbance, and social isolation. The adaptations exhibited construct validity in their ability to distinguish subgroups of RA patients varying by perceived disease severity and general health. The new language versions of the RAQoL meet the high psychometric standards of the original UK English version. The new adaptations represent valid and reliable tools for measuring QoL in international clinical trials involving RA patients.

Entities:  

Mesh:

Year:  2014        PMID: 25270915     DOI: 10.1007/s00296-014-3138-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

Review 1.  Rheumatoid arthritis.

Authors:  David L Scott; Frederick Wolfe; Tom W J Huizinga
Journal:  Lancet       Date:  2010-09-25       Impact factor: 79.321

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Measuring health status: a new tool for clinicians and epidemiologists.

Authors:  S M Hunt; J McEwen; S P McKenna
Journal:  J R Coll Gen Pract       Date:  1985-04

Review 4.  The consequences of rheumatoid arthritis: quality of life measures in the individual patient.

Authors:  L Pollard; E H Choy; D L Scott
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

5.  Adaptation and validation of the rheumatoid arthritis quality of life scale for use in Canada.

Authors:  C Neville; D Whalley; S McKenna; M Le Comte; P R Fortin
Journal:  J Rheumatol       Date:  2001-07       Impact factor: 4.666

6.  The QLDS: a scale for the measurement of quality of life in depression.

Authors:  S M Hunt; S P McKenna
Journal:  Health Policy       Date:  1992-10       Impact factor: 2.980

7.  Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis.

Authors:  András Inotai; Bernadette Rojkovich; Angéla Fülöp; Emese Jászay; Tamás Agh; Agnes Mészáros
Journal:  Rheumatol Int       Date:  2011-01-18       Impact factor: 2.631

8.  Responsiveness of generic and disease-specific health-related quality of life instruments to venous ulcer healing.

Authors:  Andrew Jull; Varsha Parag; Natalie Walker; Anthony Rodgers
Journal:  Wound Repair Regen       Date:  2010 Jan-Feb       Impact factor: 3.617

9.  Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine.

Authors:  Edward C Keystone; Millie M Wang; Mark Layton; Sally Hollis; Iain B McInnes
Journal:  Ann Rheum Dis       Date:  2012-10       Impact factor: 19.103

10.  Responsiveness of five condition-specific and generic outcome assessment instruments for chronic pain.

Authors:  Felix Angst; Martin L Verra; Susanne Lehmann; André Aeschlimann
Journal:  BMC Med Res Methodol       Date:  2008-04-25       Impact factor: 4.615

View more
  4 in total

1.  Adaptation of the osteoarthritis-specific quality of life scale (the OAQoL) for use in Germany, Hungary, Italy, Spain and Turkey.

Authors:  Jeanette Wilburn; Stephen P McKenna; Şehim Kutlay; Tamas Bender; Jürgen Braun; Concepcion Castillo-Gallego; Marta Favero; Pal Geher; Uta Kiltz; Emilio Martin-Mola; Roberta Ramonda; Matthew Rouse; Alan Tennant; Ayşe A Küçükdeveci
Journal:  Rheumatol Int       Date:  2017-02-15       Impact factor: 2.631

2.  Adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire for use in Serbia.

Authors:  Mirjana Zlatkovic-Svenda; Matthew Rouse; Marija Radak-Perovic; Roksanda Stojanovic; Nada Vujasinovic-Stupar; Biljana Lazovic-Popovic; Jeanette Wilburn; Stephen P McKenna
Journal:  Rheumatol Int       Date:  2016-10-31       Impact factor: 2.631

3.  Do ankle, hindfoot, and heel ultrasound findings predict the symptomatology and quality of life in rheumatoid arthritis patients?

Authors:  Oana Șerban; Iulia Papp; Corina Delia Bocșa; Mihaela Cosmina Micu; Maria Bădărînză; Adriana Albu; Daniela Fodor
Journal:  J Ultrason       Date:  2020-06-15

4.  Translation and validation of the Arabic version of the osteoarthritis quality of life questionnaire (OAQoL) in Saudi patients with osteoarthritis.

Authors:  Mansour AlAjmi; Sameer Al-Ghamdi
Journal:  Health Qual Life Outcomes       Date:  2021-03-17       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.